CONCORD · Concord Drugs Limited · Financials
Market Cap
944.38M INR
Shares
13.18M
Volume · Nov 13
4218
Avg daily vol (3M)
4429
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.
Revenue
787.37M
+74%
FY2026
Net Income
10.55M
+213.8%
FY2026
Operating Cash Flow
-67.66M
-281.8%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 |
|---|---|---|---|
| INR | 860.69M | 787.37M | 452.45M |
| INR | 13.48M | 13.67M | 14.31M |
| INR | 16.2M | 17.14M | 20.27M |
| INR | 28.6M | 14.73M | 6.91M |
| INR | 8.09M | 4.18M | 3.55M |
| INR | 18.59M | 10.55M | 3.36M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2025–FY2026: 0 in dividends.
Debt Profile
No verified debt profile is available yet. This does not establish that the company has no debt or covenants.